Our group identified CREBBP/EP300 mutations as predictors of poor outcomes in patients with newly diagnosed DLBCL treated with R-CHOP, while SOCS1 mutations were associated with better prognoses [36]. The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.